Insider · CIK 0001814693
Jeannette Potts
officer
Files at QURE (uniQure N.V.). First filing Jun 20, 2025, latest Mar 6, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $187k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
QURE: uniQure N.V.
QUREOct 9, 2026 · close 22.59
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | uniQure N.V. | $31k 3,412 shares | -2% | +8% from low-87% from high | |
| 39Weak | uniQure N.V. | $85k 8,578 shares | -7% | +26% from low-85% from high | |
| 38Weak | uniQure N.V. | $71k 4,670 shares | -4% | +233% from low-16% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | QURE uniQure N.V. | AGrant or award Ordinary Shares | +35,400 | $0.00 | $0 | 141,895 | Mar 6, 2026 |
| Mar 4, 2026 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -3,412 | $9.06 | $31k | 138,483 | Mar 6, 2026 |
| Mar 4, 2026 | QURE uniQure N.V. | AGrant or award Stock Option (Right to Buy)derivative | +57,200 | $0.00 | $0 | 57,200 | Mar 6, 2026 |
| Mar 2, 2026 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -8,578 | $9.95 | $85k | 106,495 | Mar 4, 2026 |
| Jun 16, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -4,670 | $15.14 | $71k | 115,073 | Jun 20, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.